Treatment rationale and design of the RAMNITA study

A phase II study of the efficacy of docetaxel + ramucirumab for non–small cell lung cancer with brain metastasis

Keiko Tanimura, MD,a Junji Uchino, MD, PhD,a,b∗ Nobuyo Tamiya, MD, PhD,a Yoshiko Kaneko, MD, PhD,a Tadaaki Yamada, MD, PhD,a Kenichi Yoshimura, PhD,b Koichi Takayama, MD, PhD,a

Abstract

Background: We described the treatment rationale and procedure for a phase II study of docetaxel plus ramucirumab for non–small cell lung cancer (NSCLC) patients with brain metastasis (RAMNITA study; University Information Network Clinical Trials Registry identification no. [UMIN]; 000024551). Combination therapy of angiogenetic inhibitor with chemotherapy improved the outcome of patients with brain metastasis in previous reports; however, the efficacy of ramucirumab, a vascular endothelial growth factor receptor-2 monoclonal antibody, for brain metastasis has not been shown.

Patients and methods: This RAMNITA study is a prospective, multicenter, open-label, single-arm phase II study designed to evaluate efficacy and safety of docetaxel and ramucirumab for advanced NSCLC patients with brain metastasis. Eligible patients will receive docetaxel (60mg/m2) and ramucirumab (10mg/kg) every 21 days until disease progression. The primary endpoint is progression-free survival (PFS), and secondary endpoints are overall survival, intracranial PFS, response rate, and safety. Sixty-five participants will be recruited from September 2017 to December 2019 and followed up for 1 year after final registration. The results from this study may suggest a treatment option for brain metastasis in NSCLC.

Ethics: The protocol was approved by the institutional review board of each study center. Written informed consent will be obtained from all patients before registration, in accordance with the Declaration of Helsinki.

Abbreviations: MRI = magnetic resonance imaging, NSCLC = non–small cell lung cancer, OS = overall survival, PFS = progression-free survival, RECIST = Response Evaluation Criteria in Solid Tumors, SRS = stereotactic radiosurgery, VEGF = vascular endothelial growth factor.

Keywords: brain metastasis, docetaxel, non–small cell lung cancer, ramucirumab, study protocol

1. Introduction

Non–small cell lung cancer (NSCLC) is usually diagnosed at an advanced stage of the disease, and brain metastasis is a common complication in NSCLC patients, with >10% of patients with NSCLC presenting with brain metastasis at their first hospital visit[1,2] and 30% to 40% of patients with NSCLC developing brain metastasis during the course of the disease.[3] Although efficacy of chemotherapy for brain metastasis is limited, radiological therapies, including stereotactic radiosurgery (SRS) and whole brain radiotherapy, or surgical resection may be used for local control of brain metastasis.

In cancer, tumor angiogenesis owing to overexpression of angiogenetic factors, such as vascular endothelial growth factor (VEGF) receptor, create an abnormal tumor microenvironment characterized by hypoxia and acidosis, and interstitial hypertension owing to vascular hyperpermeability, which reduces drug penetration into tumors. Antiangiogenetic agents can decrease tumor vascular permeability and interstitial fluid pressure by inhibiting of tumor angiogenesis, and thereby improve the efficacy of coadministered anticanccer drug(s).[4]

Previous research revealed angiogenesis via the VEGF pathway is involved in the formation of brain metastasis. Subset analysis of AVAiL trial data showed that bevacizumab combined with platinum-doublet chemotherapy significantly decreased brain metastasis development.[5] Furthermore, bevacizumab combined with cytotoxic agents improved the survival of patients with newly detected brain lesions.[6,7]

Ramucirumab is a human recombinant IgG1 monoclonal antibody that specifically binds to the extracellular domain of VEGF receptor-2 with high affinity, preventing the binding of VEGF ligands and receptor activation.[4] The REVEL study was a global, randomized, placebo-controlled, double-blind, multicenter phase III study comparing docetaxel plus ramucirumab combination treatment with docetaxel treatment (docetaxel plus
placebo) in patients with stage IV NSCLC who showed disease progression after platinum-based therapy. This study showed that second-line docetaxel plus ramucirumab combination treatment of patients with stage IV NSCLC improves progression-free survival (PFS), overall survival (OS), and response rate; however, the efficacy of ramucirumab for brain metastasis remained unclear.\(^8,^9\) The current trial is designed to evaluate the efficacy and toxicity of a docetaxel plus ramucirumab regimen as a treatment for NSCLC with brain metastasis.

2. Patients and methods

2.1. Study design

The RAMNITA study is an open-label, single-arm trial of NSCLC with brain metastasis. Figure 1 depicts a flow chart of the study. The aim of this study is to investigate the efficacy and safety of ramucirumab with docetaxel in patients with advanced or recurrent NSCLC who have brain metastasis. Patients are registered in this study after independent review by the Data Center of the Clinical Research Support Centre Kyushu, where the potential subjects are screened against the inclusion and exclusion criteria. At least annual independent monitoring is planned, in accordance with the Japanese clinical trial guideline. We plan to recruit 65 patients from September 2017 to December 2019. The observational period is 1 year from time of final registration. The primary endpoint is PFS, and secondary endpoints are OS, intracranial PFS, response rate, and safety.

2.2. Treatment

Intravenous administration of ramucirumab 10mg/kg plus docetaxel 60mg/m\(^2\) on day 1 of a 3-week cycle will be continued until disease progression or fulfillment of the criteria of treatment cessation. No dosage adjustment according to age, body weight, sex, ethnicity, and smoking status is warranted.

This study has been conducted in compliance with the principles of the Declaration of Helsinki and registered in the University Hospital Medical Information Network database (UMIN000024551).

2.3. Key eligibility criteria

Key eligible criteria are listed below.

**<Inclusion criteria>**

1. Histological or cytological confirmation as advanced NSCLC
2. Asymptomatic brain metastasis is present. SRS (including Gamma Knife or Cyber Knife) before enrollment is allowed.
3. A history of chemotherapy
4. Performance status (ECOG) is 0 or 1.
5. Age \(\geq 20\) years
6. Bone marrow, coagulation factor activity, and organ functions have all been confirmed as normal.
7. Life expectancy of at least 3 months
8. If sexually active, patients must be postmenopausal, surgically sterile, or using effective contraception.
9. Other cancers must have been treated curatively and followed without evidence of recurrence for at least 3 years before acquisition of consent.
10. Provision of written informed consent

**<Exclusion criteria>**

1. Receiving other anticancer therapy currently
2. Presenting symptoms caused by brain metastasis
3. History of whole brain radiotherapy or surgical resection for brain metastasis
4. Presence of meningeal metastasis
5. Bleeding into the brain metastasis or other central nervous system hemorrhage within 21 days before acquisition of consent
6. Intratumor cavitation or major blood vessel invasion or encasement by cancer
7. Arterial thromboembolic events, venous thromboembolism events, or serious bleeding complications within 6 months before acquisition of consent
8. Other serious complications
9. Patients who are pregnant, nursing, or possibly pregnant
10. Uncontrolled metabolic disorder, including diabetes mellitus
11. Active or uncontrolled clinically serious infection

2.4. Patient registration

After the eligibility criteria have been met and the patients have provided informed consent, eligible patients will be registered and the planned treatment will be initiated by the investigators. Accrual began in May 2017 and should continue for 3 years.

2.5. Evaluation of response and safety

Patients will be administered docetaxel and ramucirumab every 3 weeks beginning on day 1 and continue until disease progression or the fulfillment of the discontinuation criteria. Tumor assessments by imaging (brain magnetic resonance imaging [MRI] tumor and thoracoabdominal computed tomography) should be
performed as scheduled every 6 weeks (±2 weeks) during 8 months following protocol treatment commencement, and every 9 weeks (±2 weeks) thereafter, until progressive disease is documented on imaging.

The antitumor effect is evaluated according to the “New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1)—Japanese JCOG edition.”

For assessment of brain metastasis, “Brain Metastases from Solid Tumors: Implementing Response Assessments” (https://www.parexel.com/files/5214/0422/3830/MI_Brain_Metastases_White_Paper_JUN_14.pdf) will be used. Target lesions and nontarget lesions defined on gadolinium-enhanced MRI with a 3-mm maximum slice thickness.

2.6. Statistical design

From an analysis of JVCG phase II study data from patients treated by ramucirumab-docetaxel, median PFS and OS were reported to be 5.22 months (95% CI: 3.52–6.97 months) and 15.15 months (95% CI: 12.43–26.55 months), respectively.[10]

On the contrary, life expectancy for patients with brain metastasis was poor, with a median survival of only 3.4 months.[11]

As mentioned above, the threshold median PFS and expected median PFS are estimated to be 3.0 and 5.3 months, respectively. Under these conditions and assuming a 2-sided significance level of 5% and power of 75% from 1 sample nonparametric tests for a median survival time, 61 subjects are required (Nagashima K. A sample size estimation tool for one sample nonparametric tests for a median survival time [Internet]. March 21, 2016 [cited 2016 September 25]; Available from: http://nshi.jp/ejs/onesurvmst/). Allowing for dropouts, 65 subjects will be enrolled.

2.7. Ethics

The trial received ethical approval from the Ethics Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan (number: ERB-C-694-3, the last edition ver 2 04/Aug/2017). The trial is subject to the supervision and management of the Ethics Committee.

3. Discussion

Although the REVEL study showed efficacy and tolerability of the treatment regimen with starting dose of ramucirumab 10 mg/kg and docetaxel 75 mg/m², the permissible starting dose of docetaxel for East Asian patients is 60 mg/m².[9] Therefore, we are using this dose in our trial.

For assessment of the tumor response, we are using 2 sets of guidelines: Response Evaluation Criteria in Solid Tumors (RECIST) for extracranial lesions, and “Brain Metastases from Solid Tumors: Implementing Response Assessments” for intracranial lesions. Patients who received only SRS or do not need treatment for local control of their brain tumors are included in this study; therefore, the brain lesions of most of the participants are <3 cm in diameter and amenable to SRS. Brain tumors initially >1 cm in diameter can be evaluated according to the RECIST guideline. On the contrary, “Brain Metastases from Solid Tumors: Implementing Response Assessments” is suitable for evaluating brain tumors >5 mm in diameter.

4. Conclusion

To the best of our knowledge, this study is the first clinical trial of ramucirumab combination therapy for NSCLC with brain metastasis. Our study may provide new evidence about brain metastasis treatment in patients with NSCLC.

Acknowledgments

The authors thank the patients, their families, and all investigators involved in this recent study.

Author contributions

Conceptualization: Keiko Tanimura, Junji Uchino.

Formal analysis: Kenichi Yoshimura.

Funding acquisition: Junji Uchino.

Investigation: Keiko Tanimura, Nobuyo Tamiya, Yoshiko Kaneko, Tadaaki Yamada.

Supervision: Koichi Takayama.

References

[1] Eichler AF, Loeffler JS. Multidisciplinary management of brain metastases. Oncologist 2007;12:884–98.
[2] Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005;23:6207–19.
[3] Huang Q, Ouyang X. Predictive biochemical-markers for the development of brain metastases from lung cancer: clinical evidence and future directions. Cancer Epidemiol 2013;37:703–7.
[4] Eichler AF, Chung E, Kodack DP, et al. The biology of brain metastases—translation to new therapies. Nat Rev Clin Oncol 2011;8:344–56.
[5] Ilhan-Mutlu A, Oswald M, Liao Y, et al. Bevacizumab prevents brain metastases formation in lung adenocarcinoma. Mol Cancer Ther 2016;15:702–10.
[6] Tang N, Guo J, Zhang Q, et al. Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. Oncotarget 2016;7:3635–44.
[7] Besse B, Le Moulec S, Mazieres J, et al. Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): a nonrandomized, phase II study. Clin Cancer Res 2015;21:13896–903.
[8] Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010;28:780–7.
[9] Garon EB, GiuleaTE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014;384:665–73.
[10] Yoh K, Hosomi Y, Kasahara K, et al. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 2016;99:186–93.
[11] Lagerwaard FJ, Levendag PC, Nowak PJ, et al. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795–803.